Viking Therapeutics (VKTX) may be flying under the radar, but it could soon become one of the most closely watched biotech stories heading into 2026. It is a high-risk, high-reward biotech company trying to build the next generation of obesity treatments. Over the past year, the company has made significant strides in advancing its lead obesity treatment, VK2735, while strengthening its clinical pipeline and positioning its balance sheet to support multiple future catalysts. Let’s find out if it is a goo ...